期刊文献+

替米沙坦治疗原发性IgA肾病患者的临床效果 被引量:2

Clinical efficacy of telmisartan for patients with primary IgA nephropathy
下载PDF
导出
摘要 目的探讨替米沙坦治疗原发性免疫球蛋白A(IgA)肾病患者的临床效果。方法选取2018年3月至2020年3月海阳市人民医院收治的92例原发性IgA肾病患者,随机数字表法分为研究组和对照组,各46例。对照组男25例,女21例,年龄(47.3±1.1)岁。研究组男26例,女20例,年龄(47.2±1.2)岁。对照组给予常规治疗,研究组给予替米沙坦治疗。观察分析两组治疗效果以及估算肾小球过滤率(eGFR)、平均动脉压(MAP)、24 h尿蛋白水平等。结果研究组治疗总有效率为93.5%(43/46),明显高于对照组的71.7%(33/46)(P<0.05);治疗后,研究组eGFR、MAP、24 h尿蛋白为(109.2±13.9)ml/(min·1.73 m^(2))、(101.6±11.8)mmHg(1 mmHg=0.133 kPa)、(0.3±0.1)g/d,明显低于对照组的(112.6±16.1)ml/(min·1.73 m^(2))、(113.5±10.5)mmHg、(1.1±0.2)g/d(均P<0.05)。结论替米沙坦治疗原发性IgA肾病患者能有效增强治疗效果,促进患者肾功能改善,使患者尿蛋白水平明显下降,同时确保患者血压水平尽快恢复到正常范围,可推广使用。 Objective To investigate the clinical efficacy of telmisartan for patients with primary immunoglobulin A(IgA)nephropathy.Methods A total of 92 patients with primary IgA nephropathy admitted to Haiyang People's Hospital from March 2018 to March 2020 were divided into a study group and a control group by the random number table method,with 46 cases in each group.There were 25 males and 21 females in the control group;they were(47.3±1.1)years old.There were 26 males and 20 females in the study group;they were(47.2±1.2)years old.The control group took routine treatment,and the study group took telmisartan.The therapeutic effects,estimated glomerular filtration rates(eGFR),mean artery pressures(MAP),and 24 h urinary protein levels in these 2 groups were observed and analyzed.Results The total effective rate of the study group was significantly higher than that of the control group[93.5%(43/46)vs.71.7%(33/46);P<0.05].After the treatment,the eGFR,MAP,and 24 h urinary protein level were(109.2±13.9)ml/(min·1.73 m^(2)),(101.6±11.8)mmHg(1 mmHg=0.133 kPa),and(0.3±0.1)g/d in the study group,and were(112.6±16.1)ml/(min·1.73 m^(2)),(113.5±10.5)mmHg,and(1.1±0.2)g/d in the control group(all P<0.05).Conclusion Telmisartan for patients with primary IgA nephropathy can effectively enhance the therapeutic effect,promote the improvement of renal function,significantly reduce the level of urinary protein,and ensure the patients'blood pressure level to return to normal range as soon as possible,so it could be popularized.
作者 李自华 隋艳斐 Li Zihua;Sui Yanfei(Department of Geratology,Haiyang People's Hospital,Yantai 265100,China)
出处 《国际医药卫生导报》 2021年第17期2748-2750,共3页 International Medicine and Health Guidance News
关键词 替米沙坦 原发性IGA肾病 疗效 EGFR MAP Telmisartan Primary IgA nephropathy Therapeutic effect EGFR MAP
  • 相关文献

参考文献9

二级参考文献60

共引文献123

同被引文献43

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部